Last $1.03 USD
Change Today -0.01 / -0.96%
Volume 44.9K
ACUR On Other Exchanges
Symbol
Exchange
Berlin
NASDAQ CM
As of 8:10 PM 08/1/14 All times are local (Market data is delayed by at least 15 minutes).

acura pharmaceuticals inc (ACUR) Snapshot

Open
$1.03
Previous Close
$1.04
Day High
$1.04
Day Low
$1.01
52 Week High
10/10/13 - $2.23
52 Week Low
06/9/14 - $0.98
Market Cap
50.3M
Average Volume 10 Days
66.8K
EPS TTM
$-0.29
Shares Outstanding
48.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ACURA PHARMACEUTICALS INC (ACUR)

acura pharmaceuticals inc (ACUR) Related Businessweek News

No Related Businessweek News Found

acura pharmaceuticals inc (ACUR) Details

Acura Pharmaceuticals, Inc., a specialty pharmaceutical company, researches, develops, and commercializes products to address medication abuse and misuse utilizing its proprietary Aversion and Impede technologies. The company’s products include Oxecta tablets, a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain; and Nexafed, a pseudoephedrine HCl tablet that is used as a nasal decongestant in various non-prescription and prescription cold, sinus, and allergy products. It has seven additional opioid products, including hydrocodone bitartrate/acetaminophen, methadone HCl, morphine sulfate, oxycodone HCl/acetaminophen, oxymorphone HCl, and tramadol HCl tablets utilizing Aversion technology in various stages of development. The company has a license, development, and commercialization agreement with King Pharmaceuticals Research and Development, Inc. to manufacture and commercialize Oxecta products in the United States, Canada, and Mexico. Acura Pharmaceuticals, Inc. was founded in 1935 and is based in Palatine, Illinois.

15 Employees
Last Reported Date: 03/3/14
Founded in 1935

acura pharmaceuticals inc (ACUR) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $383.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $219.0K
Vice President of Technical Affairs
Total Annual Compensation: $282.0K
Vice President, Treasurer and Corporate Contr...
Total Annual Compensation: $170.0K
Vice President of Corporate Development
Total Annual Compensation: $170.0K
Compensation as of Fiscal Year 2013.

acura pharmaceuticals inc (ACUR) Key Developments

Acura Pharmaceuticals, Inc. Provides Update on its Abuse Deterrent Hydrocodone/Acetaminophen Combination Drug

Acura Pharmaceuticals, Inc. announced that the US Food and Drug Administration (FDA) advised the company that the data from its intranasal abuse liability study AP-ADF-301 (Study 301) for its AVERSION hydrocodone bitartrate with acetaminophen (hydrocodone/APAP) product candidate are insufficient to support an intranasal abuse deterrence claim. The FDA's advice was provided in response to the company's meeting with the FDA on December 5, 2013 to discuss the results of Study 301. The FDA indicated that a product will have to have an impact on ‘Drug Liking’ to support a claim of abuse-deterrence through a relevant route of abuse. Study 301 failed to achieve a statistically significant reduction in ‘Drug Liking’ (also known as Emax). The FDA's advice also questioned whether the intranasal route is a relevant route of abuse for hydrocodone/APAP products and recommended Acura identify variables that could have impacted the findings from Study 301 before considering or conducting an additional intranasal abuse liability study on its AVERSION hydrocodone/APAP product. Acura previously submitted a report to the FDA on the prevalence of abusing hydrocodone products by intranasal administration and intends to meet with the FDA to discuss the FDA's expectations in this area. Acura's plans for AVERSION hydrocodone/APAP, including a revised projected timeline for submission of the New Drug Application, will be determined following its meeting with the FDA.

Acura Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2014

Acura Pharmaceuticals, Inc. announced unaudited consolidated earnings results for the first quarter ended March 31, 2014. For the period, the company reported total revenues, net of $42,000 against $4,000 a year ago. Operating loss was $3,826,000 against $4,244,000 a year ago. Loss before income taxes was $4,088,000 against $4,218,000 a year ago. Net loss was $4,088,000 or $0.08 per basic and diluted share against $4,218,000 or $0.09 per basic and diluted share a year ago.

Acura Pharmaceuticals, Inc. to Report Q1, 2014 Results on May 05, 2014

Acura Pharmaceuticals, Inc. announced that they will report Q1, 2014 results at 5:00 PM, Eastern Standard Time on May 05, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ACUR:US $1.03 USD -0.01

ACUR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Durect Corp $1.50 USD +0.02
Johnson & Johnson $99.90 USD -0.19
Perrigo Co PLC $151.59 USD +1.14
View Industry Companies
 

Industry Analysis

ACUR

Industry Average

Valuation ACUR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 315.5x
Price/Book 3.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 116.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ACURA PHARMACEUTICALS INC, please visit www.acurapharm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.